Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in 
Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

Roolf, Catrin; Dybowski, Nikolaj; Sekora, Anett; Mueller, Stefan; Knuebel, Gudrun; Tebbe, Andreas; Escobar, Hugo Murua; Godl, Klaus; Junghanss, Christian; Schaab, Christoph

doi:10.1074/mcp.M117.067462

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

MPS-Authors

/persons/resource/persons78611

Schaab, Christoph
Cox, Jürgen / Computational Systems Biochemistry, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

http://www.mcponline.org/cgi/content/full/M117.067462/DC1
(Supplementary material)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Mol Cell Proteomics-2017-Roolf-1365-76.pdf
(Publisher version), 3MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Roolf, C., Dybowski, N., Sekora, A., Mueller, S., Knuebel, G., Tebbe, A., et al. (2017). Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. Molecular and Cellular Proteomics, 16(7), 1365-1376. doi:10.1074/mcp.M117.067462.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-DBE8-C

Abstract

Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, applications of FLT3 small molecule inhibitors have been investigated primarily in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in AML patients who were treated with the multikinase inhibitor sorafenib in addition to standard therapy. Here, we studied the sorafenib effect on proliferation in a panel of 13 FLT3-ITD- and FLT3-ITD+ AML cell lines. Sorafenib IC50 values ranged from 0.001 to 5.6 mu M, whereas FLT3-ITD-cells (MOLM-13, MV4-11) were found to be more sensitive to sorafenib than FLT3-ITD- cells. However, we identified two FLT3-ITD+ cell lines (MONO-MAC- 1 and OCI-AML-2) which were also sorafenib sensitive. Phosphoproteome analyses revealed that the affected pathways differed in sorafenib sensitive FLT3ITD(-) and FLT3-ITD+ cells. In MV4-11 cells sorafenib suppressed mTOR signaling by direct inhibition of FLT3. In MONO-MAC-1 cells sorafenib inhibited the MEK/ERK pathway. These data suggest that the FLT3 status in AML patients might not be the only factor predicting response to treatment with sorafenib.